According to @StockMKTNewz, a December 18, 2025 post highlights a list of potential IPOs for 2026, signaling an active pipeline but without confirmed tickers or dates in the post. source: @StockMKTNewz For confirmation and deal terms, traders should monitor S-1 registration statements, updates, and pricing ranges on the SEC’s EDGAR system. source: U.S. SEC Until S-1s are filed and first ranges are set, any 2026 IPO lineup remains indicative rather than final. source: U.S. SEC Equity IPO windows can coincide with broader risk-on behavior that has at times aligned with higher BTC and ETH beta relative to equities, warranting cross-asset monitoring into the pricing cycle. source: CME Group Post-listing, typical 180-day lockup expirations can add secondary supply and volatility, so map expected unlock dates once prospectuses are available. source: FINRA

According to @StockMKTNewz, OpenAI CFO Sarah Friar said an IPO is not on the cards in the near term, citing a Wall Street Journal report; source: WSJ via @StockMKTNewz. For traders, this means no near-term public listing to gain direct exposure to OpenAI, so attention may remain on existing listed AI plays and broader AI-linked crypto sentiment rather than a new equity issuance; source: WSJ via @StockMKTNewz.

According to @business, Medline is set to file publicly for an initial public offering as soon as Tuesday, in what could be the biggest U.S. listing of 2025. Source: Bloomberg/@business, Oct 28, 2025. The report cites people familiar with the matter and indicates the filing will be public, offering a near-term event for traders to monitor. Source: Bloomberg/@business, Oct 28, 2025. Once posted, the S-1 will provide audited financials, risk factors, and proposed deal terms that traders use to assess valuation and demand. Source: U.S. Securities and Exchange Commission.